OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Braunstein on Stem Cell Transplant Eligibility Criteria in Multiple Myeloma

November 9th 2023

Marc J. Braunstein, MD, PhD, discusses the evolution of stem cell transplant eligibility criteria in patients with multiple myeloma and highlights unanswered questions about the role of autologous stem cell transplantation following quadruplet induction regimens in this population.

Dr Markman on Pragmatic Clinical Trial Designs in Ovarian Cancer

November 9th 2023

Maurie Markman, MD, discusses the importance of designing clinical trials for patients with ovarian cancer that are based on real-world data and consider the increasing complexity of treatment sequencing in this disease.

Dr Slomovitz on the DUO-E and AtTEnd Trials Investigating Immunotherapy in Endometrial Cancer

November 9th 2023

Brian M. Slomovitz, MD, discusses the phase 3 DUO-E and AtTEnd trials investigating the use immunotherapy in endometrial cancer, as presented at the 2023 ESMO Congress.

Dr Leick on Limitations Associated With CAR T-Cell Therapy in Hematologic Malignancies

November 9th 2023

Mark Leick, MD, discusses the challenges and limitations associated with the use of CAR T-cell therapy across hematologic malignancies, highlighting how ongoing research may potentially ameliorate present unmet needs.

Dr Villalona-Calero on the Investigation of KB-0742 in Relapsed/Refractory Solid Tumors

November 9th 2023

Miguel Villalona-Calero, MD, discusses interim data from a phase 1/2 investigation of KB-0742 in patients with relapsed/refractory solid tumors or non-Hodgkin lymphoma and highlights the ongoing evaluation of the agent’s safety.

Dr Marshall on the FDA Approval of Fruquintinib in mCRC

November 9th 2023

John Lindsay Marshall, MD, discusses the significance of the FDA approval of fruquintinib (Fruzaqla) in patients with metastatic colorectal cancer.

Dr Baretti on the Mechanisms of Resistance Associated With FGFR2+ Cholangiocarcinoma

November 8th 2023

Marina Baretti, MD, discusses innate and acquired mechanisms of resistance in patients with unresectable, advanced, or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or rearrangements.

Dr Nathan on Updated Survival Outcomes With Tebentafusp in Metastatic Uveal Melanoma

November 8th 2023

Paul D. Nathan, MBBS, PhD, FRCP, discusses the 3-year survival data from the phase 3 IMCgp100-202 trial of tebentafusp-tebn in patients with previously untreated, HLA-A*02:01–positive metastatic uveal melanoma.

Dr Berdeja on the Current Role of BCMA-Targeted Therapies in Multiple Myeloma

November 8th 2023

Jesus Berdeja, MD, discusses the current role of BCMA-targeted therapies in multiple myeloma, and imparts advice to colleagues regarding the sequencing of bispecific antibodies and CAR T-cell therapies.

Dr Siefker-Radtke on the Efficacy of Erdafitinib vs Pembrolizumab in FGFR-Altered mUC

November 8th 2023

Arlene O. Siefker-Radtke, MD, discusses the efficacy of erdafitinib in patients with metastatic urothelial cancer with select FGFR alterations in the phase 3 THOR study.

Dr Eng on the Ongoing Investigation of Fruquintinib in Relapsed/Refractory mCRC

November 7th 2023

Cathy Eng, MD, FACP, FASCO, discusses the ongoing investigation of fruquintinib in patients with relapsed/refractory metastatic colorectal cancer.

Dr Morelli on the Ongoing Investigation of A2B530 in Advanced or Metastatic Solid Tumors

November 7th 2023

Maria Pia Morelli, MD, PhD, discusses the ongoing investigation of A2B530, a Tmod™ CAR T-cell therapy, in advanced or metastatic solid tumors and highlights forward-facing research with the agent.

Dr Etame on How Patient Socioeconomic Status Affects Cancer Care

November 7th 2023

Arnold Etame, MD, PhD, discusses the effects of a patient’s socioeconomic status on the cancer treatment options they receive.

Dr Leick on the Use of CAR T-Cell Therapy Across Hematologic Malignancies

November 7th 2023

Mark Leick, MD, discusses the varying role of CAR T-cell therapy across various hematologic malignancies, elaborating on the cause of its effectiveness in these disease spaces.

Dr Ronai on Key Advances in Melanoma Treatment Approaches

November 7th 2023

Ze'ev Ronai, PhD, discusses key advancements in the treatment of patients with melanoma, including the discovery of NRAS and BRAF mutations, as well as the development of immunotherapy approaches.

Dr DiPasquale on the Continued Investigation into Cerianna PET Scans in Breast Cancer

November 7th 2023

Allison A. DiPasquale, MD, discusses the continued evaluation of Cerianna positron emission tomography scans in patients with breast cancer and highlights the need for a multidisciplinary approach when treating patients in this population.

Dr Jänne on the Investigation of RMC-6291 in KRAS G12C-Mutated Solid Tumors

November 7th 2023

Pasi A. Jänne, MD, PhD, discusses the mechanism of action of the novel KRAS G12C RAS(ON) inhibitor RMC-6291, which is being evaluating for the treatment of patients with KRAS-mutated solid tumors.

Dr Shen on the Tolerability and Efficacy of ARX517 in mCRPC

November 7th 2023

John Shen, MD, discusses unique features associated with the use of the prostate-specific membrane antigen–directed antibody-drug conjugate ARX517 in patients with metastatic castration-resistant prostate cancer and highlights early efficacy and safety findings with this agent.

Dr Somaiah on the Peak Trial in GIST

November 7th 2023

Neeta Somaiah, MD, discusses enrollment criteria for the phase 3 Peak trial in patients with gastrointestinal stromal tumor and the advantages of this trial’s design.

Kelsen on DEI Initiatives at Columbia University in Patients With Cancer

November 6th 2023

Moshe Kelsen, MBA, discusses ongoing initiatives that aim to improve diversity, equity, and inclusion for patients with cancer receiving treatment at Columbia University.